Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsBiotechnology Equipment

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1937991

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1937991

Tissue Diagnostics Market by Product (Consumables, Instruments, Software, Services), Technology, Disease Type - Forecast to 2030

PUBLISHED:
PAGES: 420 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The tissue diagnostics market is estimated to be USD 6.74 billion in 2025 and is projected to reach USD 10.86 billion by 2030 at a CAGR of 10.0% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct & service, technology, disease type, end user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

The growing establishment of private diagnostic centers is significantly influencing the tissue diagnostics market. These centers are expanding access to advanced testing services, offering specialized pathology and laboratory solutions that were previously limited to large hospitals. By investing in modern tissue diagnostic systems, consumables, and automated workflows, private centers are enhancing the speed, accuracy, and reliability of disease detection. This trend not only increases the adoption of tissue diagnostic technologies but also supports more personalized and timely patient care, contributing to the overall growth of the market.

Tissue Diagnostics Market - IMG1

"By technology, the immunohistochemistry segment dominated the tissue diagnostics market in 2024."

Based on technology, the tissue diagnostics market is segmented into immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, special staining, and other technologies. Among these, immunohistochemistry holds a dominant position due to its broad application in detecting and visualizing specific proteins in tissue samples, which play a critical role in accurate disease diagnosis, biomarker identification, and guiding personalized treatment plans. Its ability to provide both qualitative and quantitative insights into tissue morphology and molecular expression makes it invaluable for cancer diagnostics and research. Additionally, IHC's compatibility with automated staining systems, standardized reagents, and high-throughput workflows has further accelerated its adoption in clinical laboratories, research institutions, and pharmaceutical development. Emerging technologies like ISH and digital pathology complement IHC by offering additional molecular and imaging capabilities, but the proven reliability, versatility, and established protocols of IHC continue to drive its sustained dominance in the tissue diagnostics market.

"By disease type, the breast cancer segment is projected to achieve the highest growth during the forecast period."

The tissue diagnostics market is segmented based on disease types into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer (NSCLC), and other disease types. Among these, the breast cancer segment is expected to register the highest growth during the forecast period. This rapid expansion is driven by the increasing global incidence of breast cancer, heightened awareness of early detection, and growing adoption of advanced diagnostic tools for accurate biomarker identification. Innovations in tissue diagnostics, including IHC panels and multiplex assays, are further enabling precise subtyping and risk stratification, supporting personalized treatment decisions. These factors collectively position the breast cancer segment as the fastest-growing area within the tissue diagnostics market.

"Asia Pacific is projected to be the fastest-growing regional market during the forecast period." "

The market for tissue diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is expected to register the highest growth during the forecast period. Rapidly expanding healthcare infrastructure, increasing government initiatives for early disease detection, and rising awareness about cancer screening are key factors driving market expansion in the region. Additionally, growing investments in research and development, the increasing prevalence of cancer, and the adoption of advanced diagnostic technologies in emerging economies such as China, India, and Japan are further accelerating market growth. These trends make Asia Pacific a high-potential region for tissue diagnostics in the coming years.

Break-up of the profiles of primary participants in the tissue diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in the tissue diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Epredia) (Japan), Abbott (US), Agilent Technologies (US), Merck KGaA (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Becton, Dickinson and Company (US), BioGenex (US), Bio SB (US), Cell Signaling Technology, Inc. (US), Histo-Line Laboratories (Italy), SLEE medical GmbH (Germany), Amos Scientific Pty Ltd. (Australia), Jinhua YIDI Medical Appliance Co., Ltd. (China), MEDITE Medical GmbH (Germany), StatLab Medical Products (UK), KONFOONG BIOINFORMATION TECH Co., Ltd. (China), Diagnostic BioSystems Inc. (US), 3DHISTECH (Hungary), RWD Life Science Co., Ltd. (US), Dakewe (China), Battery Ventures (Enzo Biochem Inc.) (US), Biocare Medical, LLC. (US), MILESTONE MEDICAL (Italy), Bio-Optica Milano Spa (Italy), and BioGnost d.o.o. (Croatia).

Research Coverage:

This research report categorizes the tissue diagnostics market by product & service (consumables, instruments, software, and services), technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, special staining, and other technologies), disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types), end user [hospitals, research laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users], and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the tissue diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. Competitive analysis of upcoming startups in the tissue diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tissue diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising prevalence of cancer, Growing demand for digital pathology, Increasing healthcare expenditure, Growing availability of reimbursements, and Rising establishment of private diagnostic centers), restraints (High cost of tissue diagnostic systems and Stringent regulatory requirements), opportunities (High growth opportunities of emerging economies, Growing demand for personalized medicines, Increasing number of clinical trials for cancer therapeutics), and challenges (Shortage of skilled professionals, Availability of refurbished products, and Inadequate standardization for TDx) influencing the growth of the tissue diagnostics market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the tissue diagnostics market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the tissue diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies (US), among others, in the tissue diagnostics market
Show more
Product Code: MD 2349

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET
  • 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 TISSUE DIAGNOSTICS MARKET OVERVIEW
  • 3.2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030
  • 3.3 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030
  • 3.4 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2025 VS. 2030
  • 3.5 TISSUE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030
  • 3.6 TISSUE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Rising incidence of cancer
      • 4.2.1.2 Growing demand for digital pathology
      • 4.2.1.3 Increasing healthcare expenditure
      • 4.2.1.4 Growing availability of reimbursements
      • 4.2.1.5 Rising establishment of private diagnostic centers
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High cost of tissue diagnostic systems
      • 4.2.2.2 Stringent regulatory requirements
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 High growth potential in emerging economies
      • 4.2.3.2 Growing preference for personalized medicines
      • 4.2.3.3 Increasing number of clinical trials for cancer therapeutics
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Shortage of skilled professionals
      • 4.2.4.2 Availability of refurbished products
      • 4.2.4.3 Inadequate standardization
  • 4.3 UNMET NEEDS AND WHITE SPACES
    • 4.3.1 UNMET NEEDS
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025
    • 5.6.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025
    • 5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT DATA (HS CODE 3822)
    • 5.7.2 EXPORT DATA (HS CODE 3822)
  • 5.8 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.10 INVESTMENT AND FUNDING SCENARIO
  • 5.11 CASE STUDY ANALYSIS
    • 5.11.1 CASE STUDY 1: OPTIMIZING AUTOMATED TISSUE PROCESSING EFFICIENCY TO REDUCE COST
    • 5.11.2 CASE STUDY 2: OPERATIONAL EFFICIENCY IMPROVEMENTS THROUGH MILESTONE MEDICAL TISSUE PROCESSOR IMPLEMENTATION
    • 5.11.3 CASE STUDY 3: WORKFLOW OPTIMIZATION THROUGH EXCELSIOR AS TISSUE PROCESSOR
  • 5.12 IMPACT OF 2025 US TARIFFS ON TISSUE DIAGNOSTICS MARKET
    • 5.12.1 INTRODUCTION
    • 5.12.2 KEY TARIFF RATES
    • 5.12.3 PRICE IMPACT ANALYSIS
    • 5.12.4 KEY IMPACT ON COUNTRY/REGION
      • 5.12.4.1 North America
      • 5.12.4.2 Europe
      • 5.12.4.3 Asia Pacific
    • 5.12.5 IMPACT ON END-USE INDUSTRIES
      • 5.12.5.1 Hospitals
      • 5.12.5.2 Research laboratories
      • 5.12.5.3 Pharmaceutical companies
      • 5.12.5.4 Contract research organizations (CROs)

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 IMMUNOHISTOCHEMISTRY (IHC)
    • 6.1.2 IN SITU HYBRIDIZATION (ISH)
    • 6.1.3 DIGITAL PATHOLOGY
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 SPECIAL STAINING
    • 6.2.2 MASS SPECTROMETRY IMAGING (MSI)
  • 6.3 TECHNOLOGY/PRODUCT ROADMAP
    • 6.3.1 SHORT-TERM (2025-2027) | OPTIMIZATION & STANDARDIZATION OF CORE REAGENTS
      • 6.3.1.1 Core technology development
      • 6.3.1.2 Product innovations
      • 6.3.1.3 Market adoption
    • 6.3.2 MID-TERM (2027-2030) | EXPANDED CAPABILITIES & SUSTAINABILITY
      • 6.3.2.1 Advanced technology development
      • 6.3.2.2 Product innovations
      • 6.3.2.3 Market adoption
    • 6.3.3 LONG-TERM (2030-2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT TISSUE DIAGNOSTICS PRODUCTS
      • 6.3.3.1 High-performance & integrated workflows
      • 6.3.3.2 Product innovations
      • 6.3.3.3 Market adoption
  • 6.4 PATENT ANALYSIS
  • 6.5 FUTURE APPLICATIONS
  • 6.6 IMPACT OF AI/GENERATIVE AI ON TISSUE DIAGNOSTICS MARKET
    • 6.6.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.6.2 BEST PRACTICES IN TISSUE DIAGNOSTICS MARKET
    • 6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN TISSUE DIAGNOSTICS MARKET
    • 6.6.4 FUTURE OF AI IN TISSUE DIAGNOSTICS MARKET
    • 6.6.5 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
    • 6.6.6 CLIENTS' READINESS TO ADOPT GENERATIVE AND AI-ENABLED TECHNOLOGIES IN TISSUE DIAGNOSTICS MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN TISSUE DIAGNOSTICS
      • 7.2.1.1 Eco-friendly initiatives
  • 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
  • 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 9.1 INTRODUCTION
  • 9.2 CONSUMABLES
    • 9.2.1 ANTIBODIES
      • 9.2.1.1 Primary antibodies
        • 9.2.1.1.1 Expanding clinical applications and biomarker discovery to drive market
      • 9.2.1.2 Secondary antibodies
        • 9.2.1.2.1 Rising adoption of digital pathology to boost market
    • 9.2.2 KITS
      • 9.2.2.1 Human immunohistochemistry kits
        • 9.2.2.1.1 Expanding cancer screening and biomarker testing to fuel market
      • 9.2.2.2 Animal immunohistochemistry kits
        • 9.2.2.2.1 Growing preclinical and comparative studies to propel market
    • 9.2.3 REAGENTS
      • 9.2.3.1 Blocking sera and reagents
        • 9.2.3.1.1 Rising emphasis on diagnostic accuracy to support growth
      • 9.2.3.2 Chromogenic substrates
        • 9.2.3.2.1 Increasing demand for high-sensitivity chromogenic substrates to fuel market
      • 9.2.3.3 Fixation reagents
        • 9.2.3.3.1 Growing emphasis on tissue integrity and biomarker preservation to drive market
      • 9.2.3.4 Organic solvents
        • 9.2.3.4.1 Increasing focus on solvent safety and efficiency to spur growth
      • 9.2.3.5 Proteolytic enzymes
        • 9.2.3.5.1 Need for handling complex tissue samples and multiplexed biomarker panels to facilitate growth
      • 9.2.3.6 Diluents
        • 9.2.3.6.1 Rising focus on maintaining reagent stability to support growth
      • 9.2.3.7 Other reagents
    • 9.2.4 PROBES
      • 9.2.4.1 Utilization of probes in fluorescence microscopy applications to boost market
  • 9.3 INSTRUMENTS
    • 9.3.1 SLIDE-STAINING SYSTEMS
      • 9.3.1.1 H&E stainers
        • 9.3.1.1.1 Increasing patient volume to sustain growth
      • 9.3.1.2 Special stainers
        • 9.3.1.2.1 Growing demand for targeted visualization to fuel market
      • 9.3.1.3 IHC stainers
        • 9.3.1.3.1 Growing demand for high-throughput tissue analysis and multiplex biomarker panels to drive market
    • 9.3.2 MICROTOMES
      • 9.3.2.1 Increasing demand for accurate tissue sectioning to support growth
    • 9.3.3 DIGITAL PATHOLOGY SCANNERS
      • 9.3.3.1 Growing adoption of digital imaging to propel market
    • 9.3.4 TISSUE PROCESSING SYSTEMS
      • 9.3.4.1 Rising need for automation in tissue preparation to propel market
    • 9.3.5 OTHER INSTRUMENTS
  • 9.4 SOFTWARE
    • 9.4.1 INCREASING WORKFLOW DIGITIZATION AND DATA MANAGEMENT NEEDS TO DRIVE MARKET
  • 9.5 SERVICES
    • 9.5.1 RISING ADOPTION OF COMPANION DIAGNOSTICS TO EXPEDITE GROWTH

10 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 IMMUNOHISTOCHEMISTRY
    • 10.2.1 RISING UPTAKE OF IMMUNOHISTOCHEMISTRY KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET
  • 10.3 IN SITU HYBRIDIZATION
    • 10.3.1 ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST MARKET
  • 10.4 DIGITAL PATHOLOGY
    • 10.4.1 RISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT GROWTH
  • 10.5 SPECIAL STAINING
    • 10.5.1 UTILIZATION OF SPECIAL STAINING IN CANCER DIAGNOSTICS TO PROPEL MARKET

11 TISSUE DIAGNOSTICS MARKET, BY DISEASE

  • 11.1 INTRODUCTION
  • 11.2 BREAST CANCER
    • 11.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO FUEL MARKET
  • 11.3 GASTRIC CANCER
    • 11.3.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST MARKET
  • 11.4 LYMPHOMA
    • 11.4.1 RISING INCIDENCE OF NON-HODGKIN'S LYMPHOMA IN ADULTS TO SUPPORT GROWTH
  • 11.5 PROSTATE CANCER
    • 11.5.1 GROWING RATE OF PROSTATE CANCER TO PROPEL MARKET
  • 11.6 NON-SMALL CELL LUNG CANCER
    • 11.6.1 GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET
  • 11.7 OTHER DISEASE TYPES

12 US: NUMBER OF TISSUE DIAGNOSTICS TESTS, BY SAMPLE TYPE

13 TISSUE DIAGNOSTICS MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 HOSPITALS
    • 13.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS TO DRIVE MARKET
  • 13.3 RESEARCH LABORATORIES
    • 13.3.1 RISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET
  • 13.4 PHARMACEUTICAL COMPANIES
    • 13.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET
  • 13.5 CONTRACT RESEARCH ORGANIZATIONS
    • 13.5.1 GROWING DEMAND FOR OUTSOURCING ANALYTICAL TESTING & CLINICAL TRIAL SERVICES TO BOOST MARKET
  • 13.6 OTHER END USERS

14 TISSUE DIAGNOSTICS MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 14.2.2 US
      • 14.2.2.1 High healthcare expenditure to drive market
    • 14.2.3 CANADA
      • 14.2.3.1 Rising prevalence of cancer to fuel market
  • 14.3 EUROPE
    • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 14.3.2 GERMANY
      • 14.3.2.1 Favorable government initiatives to boost market
    • 14.3.3 FRANCE
      • 14.3.3.1 Increasing demand for cancer diagnostics to propel market
    • 14.3.4 UK
      • 14.3.4.1 Rising investments in cancer research to drive market
    • 14.3.5 ITALY
      • 14.3.5.1 High incidence of cancer and geriatric population to support growth
    • 14.3.6 SPAIN
      • 14.3.6.1 Increasing cancer cases to boost market
    • 14.3.7 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 14.4.2 CHINA
      • 14.4.2.1 Increasing focus on healthcare infrastructure to boost market
    • 14.4.3 JAPAN
      • 14.4.3.1 Rise in development of advanced diagnostic products to fuel market
    • 14.4.4 INDIA
      • 14.4.4.1 Presence of large patient pool and rapdily growing healthcare sector to drive market
    • 14.4.5 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 MACROEOCNOMIC OUTLOOK FOR LATIN AMERICA
    • 14.5.2 BRAZIL
      • 14.5.2.1 Increasing burden of cancer cases to aid growth
    • 14.5.3 MEXICO
      • 14.5.3.1 Growing cancer burden to boost market
    • 14.5.4 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 OVERVIEW
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
  • 15.3 REVENUE ANALYSIS, 2022-2024
  • 15.4 MARKET SHARE ANALYSIS, 2024
  • 15.5 BRAND COMPARISON
  • 15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 15.6.1 STARS
    • 15.6.2 EMERGING LEADERS
    • 15.6.3 PERVASIVE PLAYERS
    • 15.6.4 PARTICIPANTS
    • 15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 15.6.5.1 Company footprint
      • 15.6.5.2 Region footprint
      • 15.6.5.3 Product & service footprint
      • 15.6.5.4 Technology footprint
      • 15.6.5.5 End-user footprint
  • 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 15.7.1 PROGRESSIVE COMPANIES
    • 15.7.2 RESPONSIVE COMPANIES
    • 15.7.3 DYNAMIC COMPANIES
    • 15.7.4 STARTING BLOCKS
    • 15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 15.7.5.1 Detailed list of key startups/SMEs
      • 15.7.5.2 Competitive benchmarking of key startups/SMEs
  • 15.8 COMPANY VALUATION AND FINANCIAL METRICS
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 F. HOFFMANN-LA ROCHE LTD.
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product launches and approvals
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Key strengths/Right to win
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses/Competitive threats
    • 16.1.2 DANAHER CORPORATION
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches and approvals
        • 16.1.2.3.2 Deals
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Key strengths/Right to win
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses/Competitive threats
    • 16.1.3 AGILENT TECHNOLOGIES, INC.
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Deals
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Key strengths/Right to win
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses/Competitive threats
    • 16.1.4 PHC HOLDINGS CORPORATION (EPREDIA)
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product approvals
        • 16.1.4.3.2 Deals
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Key strengths/Right to win
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses/Competitive threats
    • 16.1.5 MERCK KGAA
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Expansions
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Key strengths/Right to win
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses/Competitive threats
    • 16.1.6 ABBOTT
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
    • 16.1.7 BECTON, DICKINSON AND COMPANY
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Expansions
    • 16.1.8 SYSMEX CORPORATION
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Product launches and approvals
        • 16.1.8.3.2 Deals
    • 16.1.9 SAKURA FINETEK JAPAN CO., LTD.
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product launches and approvals
        • 16.1.9.3.2 Deals
        • 16.1.9.3.3 Expansions
    • 16.1.10 BIOGENEX
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product launches and approvals
    • 16.1.11 BIO SB
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
    • 16.1.12 CELL SIGNALING TECHNOLOGY, INC.
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Deals
    • 16.1.13 HISTO-LINE LABORATORIES
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products offered
    • 16.1.14 SLEE MEDICAL GMBH
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products offered
  • 16.2 OTHER PLAYERS
    • 16.2.1 AMOS SCIENTIFIC PTY LTD.
    • 16.2.2 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
    • 16.2.3 MEDITE MEDICAL GMBH
    • 16.2.4 SLMP, LLC
    • 16.2.5 KONFOONG BIOINFORMATION TECH CO., LTD (KFBIO)
    • 16.2.6 DIAGNOSTIC BIOSYSTEMS INC.
    • 16.2.7 3DHISTECH LTD.
    • 16.2.8 RWD LIFE SCIENCE CO., LTD.
    • 16.2.9 DAKEWE
    • 16.2.10 BATTERY VENTURES (ENZO BIOCHEM INC.)
    • 16.2.11 BIOCARE MEDICAL, LLC.
    • 16.2.12 MILESTONE SRL
    • 16.2.13 BIO-OPTICA MILANO SPA
    • 16.2.14 BIOGNOST D.O.O.
    • 16.2.15 OPTRASCAN
    • 16.2.16 CLARAPATH

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
    • 17.1.1 SECONDARY DATA
      • 17.1.1.1 Key data from secondary sources
    • 17.1.2 PRIMARY DATA
      • 17.1.2.1 Key data from primary sources
      • 17.1.2.2 Key primary participants
      • 17.1.2.3 Breakdown of primary interviews
      • 17.1.2.4 Key industry insights
  • 17.2 MARKET SIZE ESTIMATION
    • 17.2.1 BOTTOM-UP APPROACH
      • 17.2.1.1 Revenue estimation of key players
      • 17.2.1.2 Study of annual reports and investor presentations
      • 17.2.1.3 Primary interviews
      • 17.2.1.4 Growth forecast
    • 17.2.2 TOP-DOWN APPROACH
    • 17.2.3 BASE NUMBER CALCULATION
  • 17.3 MARKET FORECAST APPROACH
  • 17.4 DATA TRIANGULATION
  • 17.5 FACTOR ANALYSIS
  • 17.6 RESEARCH ASSUMPTIONS
    • 17.6.1 PARAMETRIC ASSUMPTIONS
    • 17.6.2 GROWTH RATE ASSUMPTIONS
  • 17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT
    • 17.7.1 RESEARCH LIMITATIONS
    • 17.7.2 RISK ASSESSMENT

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS
Show more
Product Code: MD 2349

List of Tables

  • TABLE 1 PROJECTED INCREASE IN CANCER PATIENTS, 2022 VS. 2035 VS. 2050, BY REGION
  • TABLE 2 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, BY TYPE, 2022 VS. 2045
  • TABLE 3 INTERCONNECTED MARKETS
  • TABLE 4 KEY MOVES AND STRATEGIC FOCUS
  • TABLE 5 IMPACT OF PORTER'S FORCES ON TISSUE DIAGNOSTICS MARKET
  • TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 8 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 12 TISSUE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 13 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025 (USD)
  • TABLE 14 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025 (USD)
  • TABLE 15 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
  • TABLE 16 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 17 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 18 TISSUE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 20 TISSUE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS, 2023-2025
  • TABLE 21 CLIENT'S READINESS TO ADOPT AI AND GENERATIVE TECHNOLOGIES IN TISSUE DIAGNOSTICS MARKET
  • TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 TISSUE DIAGNOSTICS MARKET: GLOBAL STANDARDS
  • TABLE 28 TISSUE DIAGNOSTICS MARKET: CERTIFICATIONS, LABELING, AND ECO-STANDARDS
  • TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 30 KEY BUYING CRITERIA, BY END USER
  • TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 32 TISSUE DIAGNOSTICS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • TABLE 33 TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 34 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 35 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 36 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 41 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 PRIMARY ANTIBODIES AVAILABLE IN MARKET
  • TABLE 47 TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 48 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 SECONDARY ANTIBODIES AVAILABLE IN MARKET
  • TABLE 53 TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 59 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 HUMAN IMMUNOHISTOCHEMISTRY KITS AVAILABLE IN MARKET
  • TABLE 65 TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 EUROPE: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 70 ANIMAL IMMUNOHISTOCHEMISTRY KITS AVAILABLE IN MARKET
  • TABLE 71 TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 72 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 77 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 78 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 BLOCKING SERA & REAGENTS AVAILABLE IN MARKET
  • TABLE 83 TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 84 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 EUROPE: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 CHROMOGENIC SUBSTRATES AVAILABLE IN MARKET
  • TABLE 89 TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 FIXATION REAGENTS AVAILABLE IN MARKET
  • TABLE 95 TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 EUROPE: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 100 TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 PROTEOLYTIC ENZYMES AVAILABLE IN MARKET
  • TABLE 106 TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 107 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 108 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 DILUENTS AVAILABLE IN MARKET
  • TABLE 112 TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 113 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 EUROPE: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 OTHER REAGENTS AVAILABLE IN MARKET
  • TABLE 118 TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 119 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 122 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 PROBES AVAILABLE IN MARKET
  • TABLE 124 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 125 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 129 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 130 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 131 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 136 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 H&E STAINERS AVAILABLE IN MARKET
  • TABLE 142 TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 144 EUROPE: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 146 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 SPECIAL STAINERS AVAILABLE IN MARKET
  • TABLE 148 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, Y COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 IHC STAINERS AVAILABLE IN MARKET
  • TABLE 154 TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 155 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 156 EUROPE: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 158 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 159 MICROTOMES AVAILABLE IN MARKET
  • TABLE 160 TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 161 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 EUROPE: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 165 DIGITAL PATHOLOGY SCANNERS AVAILABLE IN MARKET
  • TABLE 166 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 167 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 168 EUROPE: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 170 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 171 TISSUE PROCESSING SYSTEMS AVAILABLE IN MARKET
  • TABLE 172 TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 173 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 EUROPE: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 176 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 177 OTHER INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 178 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 179 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 180 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 182 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 183 TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 184 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 185 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 187 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 188 TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 189 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 190 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 192 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 193 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 194 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 195 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 196 EUROPE: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 197 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 198 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 199 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 200 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 201 EUROPE: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 203 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 204 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 205 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 206 EUROPE: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 208 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 209 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 210 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 211 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 213 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 214 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
  • TABLE 215 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 216 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
  • TABLE 217 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 218 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 219 EUROPE: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 221 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 222 COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040
  • TABLE 223 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 224 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 225 EUROPE: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 227 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 228 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
  • TABLE 229 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
  • TABLE 230 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 231 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 232 EUROPE: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 234 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 235 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
  • TABLE 236 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 237 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 238 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 239 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 240 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 241 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 242 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 243 EUROPE: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 244 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 245 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 246 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 247 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 248 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 249 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 250 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 251 US: NUMBER OF TISSUE DIAGNOSTICS TESTS, BY SAMPLE TYPE, 2023-2030 (NO. OF TESTS)
  • TABLE 252 TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 253 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 254 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 255 EUROPE: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 257 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 258 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 259 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 260 EUROPE: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 261 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 262 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 263 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 264 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 265 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 266 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 267 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 268 CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS
  • TABLE 269 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 270 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 271 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 272 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 273 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 274 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 275 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 276 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 278 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 279 TISSUE DIAGNOSTICS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 280 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 281 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 282 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 283 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 284 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 285 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 286 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 287 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 288 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 289 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 290 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 291 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 292 US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 293 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 294 US: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 295 US: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 296 US: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 297 US: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 298 US: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 299 US: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 300 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 301 US: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 302 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 303 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 304 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 305 CANADA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 306 CANADA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 307 CANADA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 308 CANADA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 309 CANADA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 310 CANADA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 311 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 312 CANADA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 313 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 314 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 315 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 316 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 317 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 318 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 319 EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 321 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 322 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 323 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 324 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 325 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 326 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
  • TABLE 327 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 328 GERMANY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 329 GERMANY: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 330 GERMANY: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 331 GERMANY: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 332 GERMANY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 333 GERMANY: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 334 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 335 GERMANY: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 336 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 337 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
  • TABLE 338 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 339 FRANCE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 340 FRANCE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 341 FRANCE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 342 FRANCE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 343 FRANCE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 344 FRANCE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 345 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 346 FRANCE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 347 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 348 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 349 UK: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 350 UK: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 351 UK: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 352 UK: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 353 UK: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 354 UK: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 355 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 356 UK: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 357 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 358 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
  • TABLE 359 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 360 ITALY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 361 ITALY: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 362 ITALY: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 363 ITALY: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 364 ITALY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 365 ITALY: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 366 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 367 ITALY: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 368 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 369 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 370 SPAIN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 371 SPAIN: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 372 SPAIN: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 373 SPAIN: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 374 SPAIN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 375 SPAIN: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 376 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 377 SPAIN: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 378 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 379 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 380 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 381 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 382 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 383 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 384 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 385 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 386 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 387 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 388 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 389 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 390 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 391 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 392 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 393 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 394 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 395 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 396 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 397 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 398 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 399 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 400 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 401 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 402 CHINA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 403 CHINA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 404 CHINA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 405 CHINA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 406 CHINA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 407 CHINA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 408 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 409 CHINA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 410 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 411 CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040
  • TABLE 412 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 413 JAPAN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 414 JAPAN: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 415 JAPAN: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 416 JAPAN: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 417 JAPAN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 418 JAPAN: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 419 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 420 JAPAN: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 421 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 422 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 423 INDIA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 424 INDIA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 425 INDIA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 426 INDIA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 427 INDIA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 428 INDIA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 429 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 430 INDIA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 431 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 432 REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040
  • TABLE 433 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 434 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 435 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 436 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 437 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 438 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 439 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 440 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 441 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 442 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 443 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 444 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 445 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 446 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 447 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 448 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 449 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 450 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 451 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 452 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 453 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 454 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 455 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 456 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 457 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 458 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 459 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 460 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 461 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 462 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 463 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 464 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 465 MEXICO: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 466 MEXICO: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 467 MEXICO: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 468 MEXICO: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 469 MEXICO: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 470 MEXICO: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 471 MEXICO: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 472 MEXICO: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 473 MEXICO: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 474 MEXICO: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 475 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 476 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 477 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 478 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 479 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 480 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 481 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 482 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 483 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 484 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 485 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 486 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 487 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 488 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 489 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 490 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 491 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 492 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 493 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 494 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023-2030 (USD MILLION)
  • TABLE 495 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 496 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
  • TABLE 497 TISSUE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 498 REGION FOOTPRINT
  • TABLE 499 PRODUCT & SERVICE FOOTPRINT
  • TABLE 500 APPLICATION FOOTPRINT
  • TABLE 501 END USER FOOTPRINT
  • TABLE 502 DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 503 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 504 TISSUE DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 505 TISSUE DIAGNOSTICS MARKET: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 506 TISSUE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 507 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 508 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 509 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-OCTOBER 2025
  • TABLE 510 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 511 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 512 DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-OCTOBER 2025
  • TABLE 513 DANAHER CORPORATION: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 514 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 515 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 516 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 517 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 518 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 519 PHC HOLDINGS CORPORATION: PRODUCT APPROVALS, JANUARY 2022-OCTOBER 2025
  • TABLE 520 PHC HOLDINGS CORPORATION: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 521 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 522 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 523 MERCK KGAA: EXPANSIONS, JANUARY 2022-OCTOBER 2025
  • TABLE 524 ABBOTT: COMPANY OVERVIEW
  • TABLE 525 ABBOTT: PRODUCTS OFFERED
  • TABLE 526 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 527 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 528 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022-OCTOBER 2025
  • TABLE 529 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 530 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 531 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-OCTOBER 2025
  • TABLE 532 SYSMEX CORPORATION: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 533 SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW
  • TABLE 534 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS OFFERED
  • TABLE 535 SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-OCTOBER 2025
  • TABLE 536 SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 537 SAKURA FINETEK JAPAN CO., LTD.: EXPANSIONS, JANUARY 2022-OCTOBER 2025
  • TABLE 538 BIOGENEX: COMPANY OVERVIEW
  • TABLE 539 BIOGENEX: PRODUCTS OFFERED
  • TABLE 540 BIOGENEX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-OCTOBER 2025
  • TABLE 541 BIO SB: COMPANY OVERVIEW
  • TABLE 542 BIO SB: PRODUCTS OFFERED
  • TABLE 543 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 544 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS OFFERED
  • TABLE 545 CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 546 HISTO-LINE LABORATORIES: COMPANY OVERVIEW
  • TABLE 547 HISTO-LINE LABORATORIES: PRODUCTS OFFERED
  • TABLE 548 SLEE MEDICAL GMBH: COMPANY OVERVIEW
  • TABLE 549 SLEE MEDICAL GMBH: PRODUCTS OFFERED
  • TABLE 550 AMOS SCIENTIFIC PTY LTD.: COMPANY OVERVIEW
  • TABLE 551 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: COMPANY OVERVIEW
  • TABLE 552 MEDITE MEDICAL GMBH: COMPANY OVERVIEW
  • TABLE 553 SLMP, LLC.: COMPANY OVERVIEW
  • TABLE 554 KONFOONG BIOINFORMATION TECH CO., LTD (KFBIO): COMPANY OVERVIEW
  • TABLE 555 DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW
  • TABLE 556 3DHISTECH LTD.: COMPANY OVERVIEW
  • TABLE 557 RWD LIFE SCIENCE CO., LTD.: COMPANY OVERVIEW
  • TABLE 558 DAKEWE: COMPANY OVERVIEW
  • TABLE 559 BATTERY VENTURES (ENZO BIOCHEM INC.): COMPANY OVERVIEW
  • TABLE 560 BIOCARE MEDICAL, LLC.: COMPANY OVERVIEW
  • TABLE 561 MILESTONE SRL: COMPANY OVERVIEW
  • TABLE 562 BIO-OPTICA MILANO SPA: COMPANY OVERVIEW
  • TABLE 563 BIOGNOST D.O.O.: COMPANY OVERVIEW
  • TABLE 564 OPTRASCAN: COMPANY OVERVIEW
  • TABLE 565 CLARAPATH: COMPANY OVERVIEW
  • TABLE 566 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS
  • TABLE 567 RESAERCH ASSUMPTIONS
  • TABLE 568 RISK ASSESSMENT

List of Figures

  • FIGURE 1 TISSUE DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET, 2022-2025
  • FIGURE 4 DISRUPTIVE TRENDS IMPACTING GROWTH OF TISSUE DIAGNOSTICS MARKET
  • FIGURE 5 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN TISSUE DIAGNOSTICS MARKET, 2024
  • FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 7 GROWING PREVALENCE OF CANCER CASES TO DRIVE MARKET
  • FIGURE 8 CONSUMABLES SEGMENT TO HAVE LARGEST MARKET DURING FORECAST PERIOD
  • FIGURE 9 IMMUNOHISTOCHEMISTRY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 10 BREAST CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 11 HOSPITALS SEGMENT TO HAVE LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 12 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 13 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14 NEWLY APPROVED PERSONALIZED MEDICINES (% OF ALL NEWLY APPROVED DRUGS), 2015-2024
  • FIGURE 15 TISSUE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 16 TISSUE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 17 TISSUE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 18 TISSUE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 19 TISSUE DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 20 TISSUE DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO
  • FIGURE 21 PATENT ANALYSIS FOR TISSUE PROCESSING SYSTEMS, JANUARY 2015-DECEMBER 2024
  • FIGURE 22 MARKET POTENTIAL OF AI IN TISSUE DIAGNOSTICS MARKET
  • FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 24 KEY BUYING CRITERIA, BY END USER
  • FIGURE 25 NORTH AMERICA TISSUE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 26 ASIA PACIFIC TISSUE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS, 2022-2024 (USD MILLION)
  • FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 29 US MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 30 BRAND COMPARISON
  • FIGURE 31 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 32 COMPANY FOOTPRINT
  • FIGURE 33 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 35 EV/EBITDA OF KEY VENDORS
  • FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 39 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT
  • FIGURE 44 TISSUE DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 45 TISSUE DIAGNOTICS MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 46 LIST OF PRIMARY SOURCES IN TISSUE DIAGNOSTICS MARKET
  • FIGURE 47 TISSUE DIAGNOSTICS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 48 TISSUE DIAGNOSTICS MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS
  • FIGURE 49 REVENUE ESTIMATION OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
  • FIGURE 50 TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 51 TISSUE DIAGNOSTICS BASE NUMBER CALCULATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 52 TISSUE DIAGNOSTICSMARKET MARKET: CAGR PROJECTIONS
  • FIGURE 53 TISSUE DIAGNOSTICS MARKET: DATA TRIANGULATION
  • FIGURE 54 PARAMETRIC ASSUMPTIONS IN TISSUE DIAGNOSTICS MARKET
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!